Scope of Things: Clinical Trial Simulations Save Costs, European Union AI Act, ChatGPT Matching Volunteers, More
By Clinical Research News Staff
December 19, 2024 | In this year’s last episode of the Scope of Things, host Deborah Borfitz discusses concerns surrounding obesity studies and treatments, debate over the European Union AI Act, the first international-level clinical study using secure multiparty computation, the NIH’s ChatGPT tool that matches potential volunteers to relevant studies, and more.
Joining Deborah is Orr Inbar, CEO and co-founder of QuantHealth. Together, they discuss how his company is using AI to simulate clinical trials to alleviate costs and efficiency issues for the notoriously complicated drug development process. He also shares his thoughts on where AI is heading in 2025 and beyond.
SHOW NOTES
News Roundup
Perspectives on the EU AI Act
Secure multiparty computation
Cell therapy for childhood brain cancer
- Study published in Nature
- Stanford Medicine press release
TrialGPT tool
- Study in Nature Communications
GUEST BIO
Orr Inbar, CEO and Co-Founder, QuantHealth
Orr Inbar, CEO and Co-Founder of QuantHealth, an AI-powered clinical trial design company that works with three of the top ten pharmaceutical companies globally. Orr’s technical background spans data science, biomedical research, software engineering, and artificial intelligence, all with a focus on healthcare. Drawing upon this experience, Orr founded QuantHealth to address the disparities in clinical research that he felt could be overcome with novel quantitative methods to increase the success rate of clinical trials.
The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider’s look at clinical research today.
Leave a comment